Is ipamorelin FDA approved? The regulatory status, read straight.

The short version

Here is the question people most want answered: is ipamorelin fda approved? No. Ipamorelin has never been approved as a drug by the FDA — or by any other regulatory authority, anywhere — for any indication. It was investigated, most notably for slow bowel recovery after surgery, but that program did not succeed and no approval followed ^[3].

That is not a technicality. The lack of approval reflects failed efficacy programs, not merely paperwork that never got filed. The single Phase 2 trial missed its goal ^[3], and in 2024 the FDA actually tightened ipamorelin's standing in the pharmacy-compounding system ^[7]. Today it is sold only as a research chemical, and it is banned in sport. This page lays out exactly where ipamorelin sits with the FDA, with the compounding committee, and with anti-doping authorities — read directly from the register.

Never approved as a drug

Ipamorelin is not approved by the FDA as a drug for any indication. It was developed by Novo Nordisk in the 1990s and advanced into clinical development for postoperative ileus — the only indication that reached Phase 2 ^[1][3]. That 2014 trial (114 adults, 0.03 mg/kg IV twice daily) missed its primary endpoint, with time to first tolerated meal of 25.3 hours versus 32.6 hours on placebo (p=0.15) ^[3]. No Phase 3 trial was conducted and no approved indication exists. It is marketed only as a research chemical, described "for research use only."

The 2024 compounding actions

The most recent regulatory development tightened access. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list (following nominator withdrawal in September 2024), and reviewed ipamorelin acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting ^[7]. Section 503A is the framework that governs which bulk substances compounding pharmacies may use; ipamorelin is not an approved bulk substance for compounding. In plain terms: the regulatory direction in 2024 was toward restriction, not expansion, of compounding-pharmacy access ^[7].

Is ipamorelin legal, and is it banned by WADA?

Legality and sport status are separate from drug approval. Ipamorelin is prohibited in sport at all times under the WADA Prohibited List, category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), as a growth hormone secretagogue ^[9]. Accredited anti-doping laboratories can detect it in urine — a validated LC-MS method identified ipamorelin alongside seven other GHRPs with detection limits of 0.2–1 ng/mL ^[9]. So any athlete subject to WADA testing should treat it as a banned substance with established detection. Its sale and possession as a non-approved "research chemical" sit in a separate regulatory lane from both drug approval and sport eligibility.

Why marketing outpaces the evidence

The gap between how ipamorelin is promoted and what is approved is wide, and worth naming. Clinic and online promotion for anti-aging, fat loss, and muscle gain rests largely on mechanism and short rodent studies, not on controlled human outcome trials ^[7]. A 2020 andrology review explicitly discusses the role and limitations of growth hormone secretagogues in men's-health practice, giving balanced context on the distance between marketed use and approved indications for this class ^[7]. Reading the regulatory record straight is the point of this site: an elegant mechanism and a thin, mostly-negative human file do not add up to an approved therapy — and the forward-looking honest position is to say so.